Background-Ischemia in the placenta is considered the base of the pathogenesis of preeclampsia, a pregnancy-specific syndrome in which soluble endoglin (sEng) is a prognostic marker and plays a pathogenic role. Here, we investigated the effects of hypoxia and the downstream pathways in the release of sEng. Methods and Results-Under hypoxic conditions, the trophoblast-like cell line JAR showed an increase in sEng parallel to an elevated formation of reactive oxygen species. Because reactive oxygen species are related to the formation of oxysterols, we assessed the effect of 22-(R)-hydroxycholesterol, a natural ligand of the liver X receptor (LXR), and the LXR synthetic agonist T0901317. Treatment of JAR cells or human placental explants with 22-(R)-hydroxycholesterol or T0901317 resulted in a clear increase in sEng that was dependent on LXR. These LXR agonists induced an increased matrix metalloproteinase-14 expression and activity and a significant reduction of its endogenous inhibitor, tissue inhibitor of metalloproteinase-3. In addition, mice treated with LXR agonists underwent an increase in the plasma sEng levels, concomitant with an increase in arterial pressure. Moreover, transgenic mice overexpressing sEng displayed high blood pressure. Finally, administration of an endoglin peptide containing the consensus matrix metalloproteinase-14 cleavage site G-L prevented the oxysterol-dependent increase in arterial pressure and sEng levels in mice. Conclusions-These studies provide a clue to the involvement of the LXR pathway in sEng release and its pathogenic role in vascular disorders such as preeclampsia. (Circulation. 2012;126:2612-2624 .) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
P reeclampsia is a pregnancy-specific syndrome characterized by systemic hypertension, proteinuria, and edema in the third trimester of pregnancy. 1, 2 It affects both the fetus and the mother and occurs in Ϸ5% of pregnancies. Severe preeclampsia leads to the appearance of the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets), seizures, or fetal growth restriction and can result in fetal death. Preeclampsia is thought to be the consequence of impaired placentation resulting from inadequate trophoblastic invasion of the maternal spiral arteries. 3 Abnormal placentation is an important predisposing factor for preeclampsia, whereas endothelial dysfunction appears to be central to the pathophysiological changes, possibly indicative of a 2-stage disorder characterized by reduced placental perfusion and a maternal syndrome. Hypoxia, followed by oxidative stress, has been postulated as a critical signal that initiates the pathogenic process in preeclampsia. 4, 5 Hypoxia and extracellular inflammatory signals can induce the intracellular accumulation of reactive oxygen species (ROS). 6, 7 In turn, the imbalance between ROS production and antioxidant systems induces oxidative stress that negatively affects reproductive processes, including cyclic luteal and endometrial changes, follicular development, ovulation, fertilization, embryogenesis, embryonic implantation, and placental differentiation and growth. 5 ROS-induced damage can target lipids, proteins, and DNA. In this context, endogenously oxygenated cholesterol derivatives (oxysterols) such as 24(S)-hydroxycholesterol and 22(R)-hydroxycholesterol (22-R) were identified as endogenous agonists of liver X receptors (LXRs). 8, 9 Many different oxysterols are known, and they all share a cholesterol structure with an oxygen-containing functional group such as alcohol, carbonyl, or epoxide. 10 The wide array of oxysterols encountered in human health and disease vary in origin. Their oxygen-containing functional group can be added at the sterol ring or at the side chain of cholesterol by a nonenzymatic oxidation, an enzymatic oxidation, or both. Oxysterols play a role in many biological processes, including cholesterol homeostasis, sphingolipid metabolism, platelet aggregation, apoptosis, and protein prenylation. Oxysterols are modulators of cholesterol metabolism, ranging from regulation of cholesterol synthesis to regulation of cholesterol elimination through bile acid synthesis. They also have important implications in physiopathology and have been involved in atherosclerosis, thrombosis, or hypercholesterolemia, among others. 10, 11 Moreover, oxysterols inhibit the differentiation and fusion of term primary trophoblasts by activating LXRs. 12 
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LXRs are ligand-activated transcription factors that form heterodimers with the retinoic X receptor (RXR) that, on ligand binding, regulate the expression of different target genes. 13 LXRs are now considered "sterol sensors" because they regulate the expression of key gene products that control intracellular cholesterol homeostasis through catabolism and transport. 14 -17 In addition to oxysterols, most studies on LXR activity have been validated with potent synthetic ligands such as the nonsteroidal Tularik agonist T0901317 (T09). 18 It has been reported that T09 acts selectively through LXR and in concert with its RXR heterodimerization partner. 19 Two variants of LXR, ␣ and ␤, have been described. 16 Whereas LXR-␣ is highly expressed mainly in the liver, kidney, small intestine, adipose tissue, and macrophages, the presence of LXR-␤ is ubiquitous in most tissues. 20 Oxysterols are detected at relatively high levels in the placenta, and a role for LXRs in the reproductive system and a potential application of LXR agonists in the treatment of reproductive pathologies have been suggested. 15 In addition, LXR-␣ and LXR-␤ are expressed in human and mouse trophoblasts and the placenta from early gestation. 21, 22 LXR isoforms have also been detected in several human trophoblast cell lines like JAR. 22, 23 Of note, one of the LXR target genes is human endoglin (ENG), which contains 6 putative LXR response elements in its proximal promoter region, at least 1 of which binds the LXR/RXR heterodimer to stimulate transcription and total endoglin expression in response to 22-R, T0901317, or synthetic RXR agonists. 24 The endothelial dysfunction in preeclampsia is thought to be caused by circulating factors that are released from the placenta. In preeclampsia, the maternal plasma concentration of free vascular endothelial growth factor and placental growth factor is decreased and the concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) is increased. 2 A pathogenic role for sEng has been reported, 25, 26 and there is a growing interest in elucidating the regulated expression and role of this potential therapeutic target in preeclampsia. 27 Interestingly, sera from pregnant women with preeclampsia can upregulate the levels of endoglin mRNA and induce the release of sEng in choriocarcinoma cells. 28 Endoglin is a transmembrane auxiliary receptor for transforming growth factor-␤ that modulates cellular responses to multiple members of the transforming growth factor-␤ family. 29 Endoglin is highly expressed on proliferating endothelial cells and syncytiotrophoblasts, including the trophoblast cell line JAR, 29 -31 and regulates trophoblast differentiation along the invasive pathway in human placental villous explants. 32 Of note, sEng, generated by proteolytic shedding, antagonizes the membrane-bound form. 25, 33, 34 Here, we show that the hypoxia-induced pathway involving ROS and oxysterols activates the proteolytic release of sEng, a process that can be blocked in vitro and in vivo by endoglinrelated peptides carrying a matrix metalloproteinase-14 (MMP-14) cleavage site. Moreover, mice treated with either oxysterols or LXR agonists underwent an increase in plasma sEng levels, concomitant with an increase in arterial pressure. An increase in arterial pressure was also observed in mice overexpressing MMP-14 that showed high levels of plasma sEng, supporting a role of the LXR pathway in the sEng release and its contribution to vascular homeostasis regulation.
Methods

Cell and Tissue Culture
The human placental choriocarcinoma cell line JAR, 31 human umbilical vein endothelial cells (Lonza, Walkersville, MD), and stable transfectants of rat myoblast L6E9 35 and mouse fibroblast L929 36 expressing human endoglin were grown as described. Mouse embryonic fibroblasts from wild-type (WT) and LXR knockout (Lxr␣,␤ Ϫ/Ϫ ) mice and monkey kidney COS-7 cells were grown in Dulbecco modified Eagle medium. For LXR activation studies, cells were incubated with T0901317 (Calbiochem), 22-R, or 9-cis-retinoic acid (RA; Sigma-Aldrich, L'Isle D'Abeau, France). For metalloprotease inhibition assays, cells were incubated with recombinant human tissue inhibitor of metalloproteinase (TIMP)-1, -2, or -3 (R&D Systems, Minneapolis, MN), doxycyclin (Sigma-Aldrich) or endoglin peptides. For hypoxia treatments, JAR cells were incubated with 1% O 2 or in the presence of 100 mol/L deferoxiamine mesylate salt (Sigma-Aldrich). Human fresh placental explants were collected in the delivery room of the University Hospital, Salamanca Spain, within 30 minutes of delivery from patients without complications. After removal of decidua and large vessels, 0.5 g tissue was cultured in complete Dulbecco modified Eagle medium-F12 medium. Explants were incubated for 24 hours with 5 mol/L 22-R or 15 mol/L endoglin peptides as indicated.
Plasmids and Cell Transfections
Expression vector encoding HA-tagged human endoglin in pDisplay has been described. 37 Expression vector encoding human MMP-14 was kindly provided by Dr Alicia Garcia-Arroyo (Centro Nacional Investigaciones Cardiovasculares, Madrid, Spain). Cell transfections were carried out with SuperFect Reagent (Qiagen, Crawley, UK).
Flow Cytometry
Immunofluorescence flow cytometry studies were carried out with primary monoclonal antibodies mouse anti-endoglin P4A4 and rabbit anti-MMP-14 (Abcam, Cambridge, UK), as well as with Alexa 488 anti-mouse or Alexa 647 anti-rabbit secondary antibodies. 37 For ROS detection analyses, JAR cells were subjected to hypoxia/normoxia in the presence of Trolox (Calbiochem) and incubated with 2Ј,7Ј-dichlorodihydrofluorescein diacetate (CM-H2DCFDA; Invitrogen, Carlsbad, CA), and their fluorescence was estimated.
ELISA Analysis
Concentrations of human sEng were determined by Quantikine Human Endoglin/CD105 (R&D Systems). The plasma concentra-
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Oxysterol-Induced Soluble Endoglin in Hypertension tions of mouse sEng were determined by DuoSet mouse endoglin/ CD105 (R&D Systems). Concentrations of TIMP-3 were determined with a TIMP-3 human ELISA kit (Abnova, Taiwan). All immunoassays were measured in a Varioskan Flash spectral scanning multimode reader (Thermo Scientific).
Lipid Analysis and Liposome Preparation
Lipid extraction from adherent JAR cells was carried out according to the method of Bligh and Dyer 38 in a chloroform/methanol mixture. Lipids were derivatized to trimethylsilyl ethers with bis(trimethylsilyl)trifluoroacetamide and submitted to gas chromatography-mass spectrometry analysis (Agilent 7890A; Agilent Technologies). As control markers, purified cholesterol and 22-R were used. Liposomes containing L-␣-phosphatidylcholine (Sigma) and 22-R were prepared at a molar ratio of 2:1 in PBS. When necessary, endoglin peptides were added to the mixture. The aqueous suspension was bath-sonicated for 1 hour before injection into mice.
Real-Time and Semiquantitative Reverse Transcriptase-Polymerase Chain Reaction Analysis of mRNA Levels
Total RNA was isolated from cells with the RNeasy kit (Qiagen) and reverse-transcribed with iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA). The resultant cDNA was used as a template for real-time polymerase chain reaction with the iQ SyBR-Green Supermix (Bio-Rad). Amplicons were detected with an iQ5 real-time detection system. For semiquantitative reverse transcriptase-PCT (RT-PCR), cDNA was subjected to PCR amplification with the HotMaster Taq DNA polymerase kit (5 Prime Inc, Gaithersburg, MD) with human TIMP-2, TIMP-3, and glyceraldehyde-3-phosphate dehydrogenase primers. PCR products were separated by agarose gel electrophoresis and documented in a Gel Doc XR System (Bio-Rad, Hercules, CA), and bands were quantified with the use of Quantity One software.
RNA Interference Experiments
The human small interfering ribonucleic acids (siRNA) for TIMP-3, hypoxia-inducible factor-1␣, and scrambled siRNA were from Ambion Inc (Austin, TX). JAR cells were transfected with siRNA with lipofectamine 2000 (Invitrogen).
Metalloproteinase Activity
The metalloproteinase activity of JAR cells or placental explants was determined with the fluorogenic peptide Mca-PLGL-Dpa-AR-NH2 (R&D Systems). For cell-free assays, recombinant human MMP-14 (Millipore) was activated by incubation with 4-aminophenylmercuric acetate (Sigma). When necessary, the metalloproteinase activity was determined in the presence of 30 mol/L endoglin peptides or 50 mol/L doxycyclin.
Endoglin Peptides and Recombinant Protein
Short endoglin-related peptides P583 (TSKGLVLP), P447 (SLSFQLGLYL), and P230 (GPRTVTVK) with N-terminal acetylation and C-terminal amidation were synthesized and purified to Ͼ90% purity (Biomedal SL, Sevilla, Spain). Recombinant human endoglin encoding the extracellular domain (Glu26-Gly586) was purchased from R&D Systems Inc.
Mice and In Vivo Experiments
Mice from the C57BL/6J strain (male; age, 8 -12 weeks) were infused intraperitoneally with T09 (40 -50 mg/kg), 22-R (40 -50 mg/kg), or vehicle alone (ethanol-saline solution 1:1) daily during 4 to 6 days. Alternatively, male or pregnant female (20 weeks old, third week of gestation) mice were intravenously injected in the tail vein with a liposome mixture containing 22-R (40 -50 mg/kg) and L-␣-phosphatidylcholine at a molar ratio of 1:2 in the presence or absence of 60 g peptides per 1 g body weight per day. To upregulate in a tetracycline-dependent manner the endogenous MMP-14, Ola129/C57BL/6J knock-in mice were generated. A reg-ulatory cassette was inserted immediately upstream of its translation initiation codon so that gene expression could be regulated by dietary doxycycline administration. Recombinant clones of embryonic stem cells containing the MMP-14 regulatory cassette were used to generate germline-transmitting chimeras by aggregation in morulas. Chimeric mice were bred with C57BL/6J females, and genotypes were determined by Southern blot analysis of tail DNA. Upregulation of MMP-14 was induced when mice were 5 weeks old. To generate transgenic mice expressing sEng (Sol.eng ϩ ), a truncated endoglin construct (amino acids 26 -437) driven by a ubiquitous actin promoter was microinjected into CBAxC57BL/6J fertilized eggs. Progeny was screened for endoglin transgene by PCR analysis of tail DNA. Studies reported here were performed in the F7 generation. The concentration of total protein in urine was measured by a colorimetric assay (Bradford Method). Systolic arterial pressure was measured in conscious mice with a tail cuff sphygmomanometer (NIPREM 546) equipment; in conscious, freely moving mice by radiotelemetry using a catheter implanted into an artery of the mouse attached to an implantable microminiaturized monitor (PA-C20, Data Sciences Intl); or in anesthetized mice using an intracarotid cannula connected to a blood pressure transducer. All of the experiments were approved by the appropriate institutional animal care and use committees.
Statistics
Data were subjected to statistical analysis, and results are shown as meanϮSEM. Differences in mean values between 2 groups were analyzed with the Student t test (unpaired). Comparisons of several groups were done by 1-way (a single variable) or 2-way (two variables) ANOVA. Then, a posteriori t test was used for group comparisons (GraphPad Software). Additional information is given in the online-only Data Supplement.
Results
Hypoxia Induces sEng Shedding
Because hypoxia is a key event in the development of preeclampsia 1,2,4 and the increase of sEng is a prognosis marker for this pathology, 25 we assessed whether hypoxia is involved in the sEng release to the media. Thus, JAR cells were either incubated under 1% oxygen or treated with deferoxiamine mesylate salt for 24 hours. Then, conditioned media were collected and analyzed by ELISA. As shown in Figure 1A , both types of hypoxic stimuli significantly induced the shedding of sEng to the media. Similarly, sEng was increased in supernatants from either myoblast or fibroblast stable transfectants expressing endoglin when submitted to hypoxia ( Figure 1B ). Because the expression of human endoglin cDNA in these cell transfectants is driven by a viral promoter, these results exclude the possibility of a transcriptional regulation or an alternative splicing event and strongly suggest the existence of a proteolytic mechanism in the sEng formation during hypoxia. That hypoxia is involved in sEng release was further supported by RNA depletion studies of hypoxia-inducible factor-1␣, a downstream component of the hypoxia pathway. Thus, siRNA-mediated knockdown of hypoxia-inducible factor-1␣ was carried out in JAR cells, subjected or not subjected to hypoxia, using 3 different siRNAs, and silencing of hypoxia-inducible factor-1␣ was monitored by quantitative RT-PCR ( Figure 1C ). Analysis by ELISA of the corresponding cell supernatants shows a marked decrease in the hypoxia-induced upregulation of sEng ( Figure 1D ). There is increasing evidence that the high levels of sEng in preeclampsia are associated with both increased oxidative stress and reduced antioxidant defenses. 2,5 Thus, we wondered whether hypoxia was able to promote not only the shedding of sEng but also the formation of ROS in JAR cells. Thus, JAR cells were submitted to hypoxia for 24 hours and then incubated with the ROS reactive probe CM-H2DCFDA. As evidenced by flow cytometry, ROS formation was induced in hypoxic JAR cells ( Figure 1E ). Moreover, this increase in the ROS formation was significantly blocked by treatment with Trolox, a potent antioxidant derived from vitamin E ( Figure 1E ). Interestingly, Trolox also induced a clear reduction in the sEng levels shed under hypoxic conditions ( Figure 1F ). These results suggest that ROS are a downstream component of the hypoxia pathway that leads to an increase of sEng.
Oxysterols Are Involved in the Shedding of sEng via the LXR Pathway
One of the effects of hypoxia-induced ROS in the cell is the generation of oxysterols. 39 Indeed, JAR cells subjected to hypoxia showed an increased production of 22-R compared with normoxic cells ( Figure I in the online-only Data Supplement). Because oxysterols signal through the LXR receptors 17 and total endoglin expression is induced by the activa-tion of the LXR pathway mediated by the LXR synthetic agonist T09, 24 we assessed the involvement of this pathway in the production of sEng. As expected, the treatment of JAR cells with T09 resulted in a clear increase in cell surface endoglin ( Figure II in the online-only Data Supplement). In addition, treatment with T09, as well as with the physiological LXR ligand, the oxysterol 22-R, and the RXR ligand RA, induced a potent release of sEng ( Figure 2A ). Interestingly, 22-R and RA showed a positive synergistic cooperation in the release of sEng levels. Moreover, when primary cultures of human endothelial cells treated with the synthetic LXR agonist T09 were used, a clear upregulation of sEng levels was observed ( Figure 2B ). That the pathway of the nuclear receptor LXR is involved in sEng shedding was confirmed with the use of mouse embryonic fibroblasts derived from Lxr␣,␤ Ϫ/Ϫ double-knockout mice. On transfection with human endoglin, WT mouse embryonic fibroblasts showed an increased shedding of sEng in the presence of T09, whereas Lxr␣,␤ (Ϫ/Ϫ) mouse embryonic fibroblasts did not show any significant response to the LXR agonist ( Figure 2C P<0.002 P<0.003 Figure 1 . Effect of hypoxia on soluble endoglin (sEng) release. A, JAR cells were incubated with deferoxiamine mesylate salt (DFO) or 1% oxygen for 24 hours, and sEng levels were measured by ELISA (nϭ3 in each group). B, Rat myoblast (L6E9) and mouse fibroblast (L929) stable transfectants expressing human endoglin were incubated under hypoxic conditions (1% oxygen) for 24 hours, and sEng levels were measured by ELISA (nϭ3 in each group). C and D, JAR cells were transfected with 3 different small interfering RNA (siRNA) to silence HIF-1␣. After 24 hours, real-time reverse transcriptase-polymerase chain reaction was used to measure hypoxiainducible factor-1␣ (HIF-1␣) expression (C), whereas sEng levels were determined by ELISA (D). Untreated control cells (CTL) and cells transfected with scrambled siRNA (siSC) are included. Statistical analyses of siRNA samples compared with CTL are indicated (siRNA#1 vs siSC under normoxia; siRNA#1, #2, and #3 vs siSC under hypoxia; nϭ3 in each group). E and F, JAR cells were subjected to hypoxic conditions (1% oxygen) either in the presence or in the absence of the antioxidant Trolox. After 24 hours, media were removed and sEng levels were measured by ELISA (F). Then, cells were incubated with 2Ј,7Ј-dichlorodihydrofluorescein diacetate (CM-H2DCFDA), a cellpermeant indicator for reactive oxygen species (ROS), and their fluorescence was analyzed by flow cytometry to determine the levels of ROS formation (E; nϭ3 in each group).
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cDNA displayed increased levels of sEng in the presence of T09 ( Figure 2D ). Because the expression of endoglin cDNA in these cells is driven by a potent viral promoter, these results exclude a possible transcriptional regulation in the generation of sEng and provide support for the proteolytic processing of the membrane-bound endoglin activated by the LXR pathway.
LXR Modulates the Proteolytic Cleavage of Endoglin Through the MMP-14 Inhibitor TIMP-3
Because MMP-14 mediates endoglin shedding 33 and the MMP-14 inhibitor TIMP-3 has been reported as a target gene of the LXR pathway, 40 we assessed whether TIMP-3 expression was modulated by hypoxia and LXR in JAR cells. As evidenced by quantitative RT-PCR, hypoxia markedly decreases mRNA levels of TIMP3 but leaves the transcript levels of TMP-2 unaffected ( Figure 3A , left). Treatment with T09 leads to a significant reduction in TIMP-3 mRNA, as evidenced by semiquantitative RT-PCR ( Figure 3A , right). In addition, TIMP-3 protein levels were downregulated in JAR cells treated with the LXR ligands T09 and 22-R ( Figure 3B ). To further confirm the involvement of TIMP-3, siRNAmediated knockdown was carried out in JAR cells using 3 different siRNAs, and silencing of TIMP-3 was monitored by quantitative RT-PCR ( Figure 3C ). Analysis by ELISA of the corresponding conditioned supernatants shows an increase in sEng levels on TIMP-3 interference ( Figure 3D ). Conversely, incubation of JAR cells with recombinant human TIMP-3
showed a marked inhibition of the sEng levels induced by T09 ( Figure 3E ). In the same experiment, TIMP-1 showed a weak inhibitory effect, whereas TIMP-2 was able to reduce the levels of sEng greatly ( Figure 3E ), suggesting that the protease involved in the endoglin shedding is a common target for TIMP-3 and TIMP-2.
MMP-14 Is Involved in the Shedding of Endoglin in JAR Cells
TIMP-2 and TIMP-3 are inhibitors of MMP-14, which has recently been described as an endoglin-shedding protease in endothelial cells. 33 Therefore, we decided to study the role of MMP-14 in endoglin shedding from JAR cells. As shown in Figure 4A , sEng levels in the culture media from JAR cells overexpressing MMP-14 are significantly increased compared with controls. Similarly, coexpression of MMP-14 and human endoglin in COS-7 cells led to a clear increase in the levels of sEng ( Figure 4B ). Because T09 downregulates the MMP-14 inhibitor TIMP-3 (Figure 3 ), we next wondered whether the treatment of JAR cells with this LXR agonist increased the MMP-14 activity. To this end, we used the fluorogenic peptide Mca-PLGL-Dpa-AR-NH 2 , which is specifically recognized as a substrate of MMP-14. As shown in Figure 4C , the MMP-14 activity was markedly enhanced in response to T09. As a control, this enhancement was abolished in the presence of doxycycline, a broad-spectrum protease inhibitor. Interestingly, the MMP-14 cleavage site G-L, present in the specific fluorogenic peptide, was identi- A and B; nϭ3) . C, Murine embryonic fibroblasts (MEFs) from wildtype (WT) or LXR␣,␤ double-knockout (2-KO) mice were transfected with an expression vector encoding human endoglin or an empty vector (EV) before treatment with LXR ligands. Differences between WT and LXR 2-KO mock-and endoglin-transfected MEFs were analyzed with 2-way ANOVA, followed by t test; nϭ3. D, Rat myoblast (L6E9) and mouse fibroblast (L929) stable transfectants expressing human endoglin were incubated with LXR ligands as indicated (nϭ3). Statistical differences between each group and its control were assessed by 1-way ANOVA followed by t test.
fied in 2 juxtamembrane peptides of the endoglin extracellular domain. This finding prompted us to postulate a possible modulatory effect of these peptides on endoglin shedding. For this purpose, 3 endoglin peptides were synthesized ( Figure  4D ). Incubation in a cell-free system of recombinant MMP-14 with a fluorogenic substrate in the presence of peptides P447 and P583 showed that these peptides, alone or combined, significantly inhibited MMP-14 activity, suggesting that these endoglin sequences are targets of MMP-14. As a negative control, incubation with the endoglin peptide P230, lacking the GL motif, did not affect the MMP-14 activity. Because peptide P583 showed the strongest inhibitory effect and the relative position of its cleavable GL motif fits well with the reported size of sEng, 33 it was selected for further studies. To assess whether peptide P583 could compete with the proteolytic processing of membrane-bound endoglin, sEng levels of JAR cells were measured in the presence of endoglin peptides. Peptide P583 but not P230 significantly inhibited the basal sEng shedding, suggesting that this endoglin sequence mimics the natural sequence of membrane-bound endoglin, interfering with the proteolytic activity of MMP-14 ( Figure 4E ). As a control, incubation with the protease inhibitor doxycycline rendered levels of inhibition similar to P583. Because MMP-14 activity is induced by LXR ligands (Figure 4C ), we next assessed whether MMP-14 expression was also modulated by the LXR pathway. Indeed, incubation of JAR cells with different combinations of LXR ligands (T09, RA, and 22-R) and under hypoxic conditions resulted in an upregulated expression of the cell surface MMP-14 ( Figure 4F and Figure III in the online-only Data Supplement). The effect of 22-R was also tested on human placental explants ( Figure 4G-4I ). In the presence of 22-R, sEng levels were significantly enhanced compared with controls, and this increase was inhibited by peptide P583 but not by P230 ( Figure 4G ). Similar to JAR cells, sEng levels paralleled MMP-14 activities in each treatment condition ( Figure 4H ), and soluble TIMP-3 levels were significantly inhibited in the presence of 22-R ( Figure  4I ) in human placental explants.
Activation of the LXR Pathway In Vivo Augments Serum Levels of sEng and Systolic Arterial Pressure
Next, we investigated whether our results with cultured cells could be reproduced in an animal model. To this purpose, , or 1% oxygen for 24 hours as indicated. The conditioned media were collected, and TIMP-3 levels were measured by ELISA. Every treatment was compared with the control (nϭ3; 1-way ANOVA followed by t test). C and D, JAR cells were transfected with 3 different small interfering RNA (siRNA) to silence TIMP-3. After 24 hours, real-time RT-PCR was used to measure TIMP-3 expression (C), whereas soluble endoglin (sEng) levels were determined by ELISA (D). A scrambled siRNA (siSC) was also transfected as a control (CTL vs siSC; siRNA#1, #2, and #3 vs siSC; nϭ3 in each group; 1-way ANOVA followed by t test). E, JAR cells were treated with recombinant TIMP-1, -2, and -3 proteins for 24 hours, and sEng levels were analyzed with ELISA (nϭ3 in each group; 1-way ANOVA followed by t test). Figure 5A and 5B shows that the systolic arterial pressure, measured by tail cuff and telemetry, was steadily increased during treatment with both ligands. Similarly, pregnant female mice treated with 22-R displayed a marked increase in systolic arterial pressure, as evidenced by tail cuff and direct intracarotid measurements ( Figure 5C ). Of note, parallel measurements of diastolic and mean arterial pressure in mice treated with 22-R ( Figure 5B ) showed a response similar to systolic arterial pressure ( Figure IV in the online-only Data Supplement). All mice treated with T09 or 22-R showed increased levels of sEng ( Figure 5D-5F ). In addition, mice treated with 22-R presented proteinuria ( Figure V in the online-only Data Supplement), a symptom associated with preeclampsia.
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The putative pathogenic role in vivo of MMP-14 and its product sEng in the hypertensive response was assessed by studying 2 different mouse models in which MMP-14 or sEng is overexpressed. Transgenic mice with a conditionally regulated MMP-14 allele were generated so that MMP-14 gene expression could be regulated by dietary doxycycline administration ( Figure 6A and 6B and Figure VI in the online-only Data Supplement). In the presence of doxycycline, transcription of MMP-14 is blocked, whereas in the absence of doxycycline, MMP-14 expression is stimulated. Interestingly, upregulation of MMP-14 in the knock-in mice after 4 months was associated with an increase in systolic arterial pressure ( Figure 6C ) and plasma levels of sEng ( Figure 6D ). Of note, 2 months after upregulation of MMP-14, the arterial pressure was unaffected, although a small increase in plasma sEng R; B, C, E, and F) or vehicle. During treatment, the systolic arterial pressure was measured daily with a tail cuff sphygmomanometer (A-C) or by telemetry (B). On the last day of treatment, tail cuff measurements were confirmed with an intracarotid blood pressure transducer in pregnant females (C). On the last day of treatment, mice were euthanized, serum samples were collected, and the soluble endoglin (sEng) levels were determined by ELISA (D-F). The number (n) of animals used in each treatment is indicated. Analysis was done by 2-way ANOVA with 1 fixed factor (treatment) and repeated measures (time); for every time point, the t test was made (control vs treatment) in A through C. In A, from day 4 of treatment, there is a statistical difference between T09 and control (CTL) group (t test, confidence levelϭ0.005). In B, from day 2, there is a statistical difference between the 22-R and control groups in tail cuff and telemetry measurements, respectively (t test, confidence levelϭ0.005). In C, there is a statistical difference from day 2 between the 22-R and control groups (t test, confidence levelϭ0.001 in day 2 and 0.005 in day 3). ***PϽ0.001; **PϽ0.005. In D through F, differences were assessed by t test.
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Oxysterol-Induced Soluble Endoglin in Hypertension could be measured, suggesting that the increased arterial pressure is not a consequence of the tetracycline removal per se but is dependent on the increased MMP activity. Similarly, transgenic mice overexpressing human sEng (Sol.eng ϩ ) and with high plasma levels of human sEng (2050Ϯ618 ng/mL; undetectable in WT mice) showed increased levels of systolic arterial pressure compared with WT animals (Figure 6E and  6F ). In addition, systolic, mean, and diastolic arterial pressures were higher in Sol.eng ϩ mice (137Ϯ7, 119Ϯ6, and 102Ϯ6 mm Hg, respectively; nϭ5) than in WT male mice (106Ϯ6, 94Ϯ6, and 81Ϯ5 mm Hg, respectively; PϽ0.05 versus Sol.eng ϩ ). Nonpregnant Sol.eng ϩ females showed a systolic arterial pressure (tail cuff method; 121.7Ϯ4.1 mm Hg; nϭ7) significantly higher than that of nonpregnant WT females (108.6Ϯ0.4 mm Hg; nϭ7; PϽ0.05). When pregnant, Sol.eng ϩ females showed a slight increase in arterial pressure (123.4Ϯ2.7 mm Hg), whereas there was a slight decrease in arterial pressure (106.4Ϯ2.8 mm Hg) in pregnant WT animals. Furthermore, when Sol-eng ϩ females were crossed with CD1xC57BL/6J hybrid males, there were significant changes in litter size and pup weight. The average weight of pups from Sol-eng ϩ mothers (5 litters, 35 pups) was 0.90Ϯ0.03 g compared with 1.21Ϯ0.003 g in WT mothers (PϽ0.001; 6 litters, 53 pups). Moreover, the number of pups per litter was significantly lower in Sol.eng ϩ mothers (6.8Ϯ0.6) than in WT mothers (8.7Ϯ0.9; PϽ0.01). When Sol.eng ϩ male mice were crossed with female CD1xC57BL/6J hybrids (36 litters, 234 pups), the number of pups per litter was similar to that of hybrid/hybrid (24 litters, 153 pups) crosses (6.36Ϯ0.51 in WT/WT and 6.5Ϯ0.27 in Sol.eng ϩ /WT). Although Sol.eng ϩ transgenic mice showed mainly normal kidney histology, dilated tubules containing hyaline casts in the medullary area and focal areas of inflammatory infiltrates were observed ( Figure 6G ). These findings are probably associated with increased protein content in the tubular fluid. Thus, the excess of sEng gives a phenotype that resembles preeclampsia (hypertension, small pup size, proteinuria, and renal damage). These results suggest that both MMP-14 and circulating sEng may contribute to the hypertensive phenotype.
Endoglin Peptide Can Inhibit Oxysterol-Induced Endoglin Shedding and Systolic Arterial Pressure
Because the endoglin peptide P583 can interfere with the MMP-14 activity and the proteolytic processing of membrane-bound endoglin in vitro, we assessed its effects in vivo. Intravenous injection of the oxysterol 22-R led to a marked increase in systolic arterial pressure that was clearly inhibited by coadministration of P583 ( Figure 7A ). Of note, P583 also reduced the levels of sEng ( Figure 7B ), suggesting that the oxysterol-dependent hypertensive effect of this animal model is mediated by sEng. In contrast, coinjection of 22-R and the endoglin peptide P230 did not affect the systolic arterial pressure or the sEng levels.
Discussion
Preeclampsia is one of the most severe complications of pregnancy. It is responsible for the highest rates of morbidity and mortality for both pregnant women and neonates. Even though over the last 20 years a great deal of evidence has accumulated on the pathophysiology of preeclampsia, the exact underlying mechanism remains to be elucidated. It is commonly accepted that its pathogenesis is associated with a hypoxic placenta. Placental hypoxia is responsible for the maternal vascular dysfunction via the increased placental release of antiangiogenic factors such as sFlt-1 and sEng. These soluble receptors bind vascular endothelial growth factor, placental growth factor, and members of the transforming growth factor-␤ superfamily in the maternal circu-lation, contributing to endothelial dysfunction in the maternal tissues. 26 Normal pregnancy is also characterized by systemic inflammation, oxidative stress, and alterations in levels of angiogenic factors and vascular reactivity. Both the placenta and maternal vasculatures are major sources of ROS and reactive nitrogen species that can produce powerful prooxidants that covalently modify proteins and alter vascular function in preeclampsia. Recent studies have shown that reduced uteroplacental perfusion causing placental ischemia results in an increase in serum sFlt-1 and sEng levels, thus firmly linking placental ischemia to upregulation of these antiangiogenic factors. 27 However, these studies have not elucidated the mechanism underlying the ischemia-induced upregulation of these antiangiogenic factors. Here, we have focused on the sEng shedding mechanism, dissecting the pathway involved ( Figure 8 ). Our data suggest that increased levels of sEng are a consequence of hypoxia, as demonstrated with experiments in JAR cells and stable cell transfectants expressing human endoglin, as well as by hypoxia-inducible factor-1␣ silencing experiments (Figure 1 ). The triggering of the hypoxia pathway involves the generation of ROS ( Figure  1E and 1F ). This finding fits well with the increased levels and the postulated pathogenic role of ROS in preeclampsia. 5 Because cholesterol is a natural target of the ROS reactivity yielding oxysterols, we then assessed the possible involvement of oxysterols and their specific LXR receptor in the generation of sEng. We found that oxysterols enhance sEng levels acting at 3 different levels. Thus, oxysterols increase cell surface endoglin in agreement with a previous report 24 ; increase the cell surface expression of MMP-14, a membranebound protease that can cleave cell surface endoglin 33 ; and inhibit the expression of TIMP-3, an inhibitor of MMP-14.
The net oxysterol-dependent upregulation of sEng is specifically dependent on the LXR pathway, as demonstrated in LXR␣,␤ Ϫ/Ϫ murine embryonic fibroblasts, suggesting that LXRs play a pivotal role in the sEng shedding ( Figure 2C ). Because normal pregnancy is associated with an enhanced oxidation of LDL particles and in preeclamptic pregnancies there is evidence of abnormally enhanced production of lipid During the treatment, systolic arterial pressure was measured daily with a tail cuff sphygmomanometer (A). On the last day of treatment, mice were euthanized, serum samples were collected, and the soluble endoglin (sEng) levels were determined by ELISA (B). The number (nϭ4) of animals used in each treatment is indicated. Analysis was done by 2-way ANOVA with 1 fixed factor (treatment) and repeated measures (time); for every time comparisons, t test was made (22-R-treated samples vs untreated group; there is a statistical difference from day 2 between the 22-R and control groups; t test, confidence levelϭ0.005). In 22-R/P583-treated samples vs the 22-R/P230 -treated group, there is a statistical difference from day 2 (confidence levelϭ0.005).
peroxides in maternal blood, 41 it can be speculated that an increased internalization of oxysterols in trophoblasts might activate LXR and increase membrane and sEng levels. In this regard, human trophoblasts have been shown to express very high levels of surface endoglin. 30 Of note, several lines of evidence support the involvement of the LXR pathway in trophoblast biology. Thus, oxysterols inhibit differentiation and fusion of term primary trophoblasts via LXR. 12 In addition, lipids from oxidized low-density lipoprotein and other LXR agonists modulate human trophoblast invasion by activating LXRs. 21, 42 Because endoglin expression regulates trophoblast differentiation and invasion of extravillous trophoblasts, 32, 43 it will be interesting to dissect the specific contribution of the LXR-induced soluble form of endoglin in these processes.
Although the activation of the LXR pathway leads to an enhanced transcription and, in turn, increased surface expression of endoglin, 24 our data indicate that the oxysterolinduced concentrations of sEng are due not only to the higher amounts of surface endoglin but also to the increased activity of MMP-14. Supporting this view, stable cell transfectants of endoglin, which lack the LXR-responsive elements in the endoglin promoter, 24 are also able to induce shedding of sEng in response to the activation of LXR ( Figure 2D ). One target gene of LXR is TIMP-3 (Figure 3) , a member of a family of 4 secreted proteins (TIMP-1-TIMP-4) that are endogenous inhibitors of MMPs. Because TIMP-3 is an inhibitor of MMP-14, the downregulation of TIMP-3, triggered by LXR, may lead to activation of MMP-14. Our data not only support this view but also provide evidence for an upregulation of the MMP-14 levels at the cell surface on LXR activation ( Figures  3 and 4 ), suggesting that gene expression of TIMP-3 and gene expression of MMP-14 are timely coordinated to regulate sEng shedding. Interestingly, the in vitro results were confirmed by experiments in vivo. Thus, administration of T09 or the oxysterol 22-R to mice led to a marked increase in the levels of sEng ( Figure 5 ). Compatible with the involvement of MMP-14 in this process, we found that MMP-14 -overexpressing mice also showed increased levels of sEng compared with WT mice ( Figure 6D ). On the basis of the capacity of the endoglin peptide P583, containing the GL cleavage motif, to interfere with the MMP-14 activity and the proteolytic processing of membrane-bound endoglin in vitro, we studied the effects of this peptide in vivo. Intravenous coinjection of P583 with the oxysterol 22-R led to an abolishment of the LXR-induced shedding of sEng, suggesting that this peptide may be a useful therapeutic drug.
The in vivo experiments showed that administration of the LXR agonist T09 or the oxysterol 22-R induced not only increased levels of sEng but also a marked increase in arterial pressure. This is in agreement with the association between a common polymorphism in the LXR-␤ gene and preeclampsia, 44 the increase in sEng in preeclampsia, and the reported pathogenic role of sEng in hypertension. Further support for this hypothesis was obtained from transgenic mice overexpressing human sEng that displayed a clear increase in arterial pressure associated with high levels of circulating sEng ( Figure 6F ). These data underline the importance of the oxysterol/LXR pathway in modifying arterial pressure.
Treatment of hypertension is especially needed in preeclampsia owing to the absence of effective therapies. However, some hope may arise from the in vivo studies using the endoglin peptide P583. Indeed, intravenous coinjection of P583 with the oxysterol 22-R led to the inhibition of the LXR-induced systolic arterial pressure. Because the sequence of P583 corresponds to TSKGLVLP (amino acids 583-590), which includes the MMP-14 cleavage site GL, the likely mechanism of action for P583 is the competition with membrane endoglin for MMP-14 cleavage. An obvious potential application of these studies is the therapeutic use of this kind of peptide in preeclamptic women to counteract the pathogenic effect of the elevated circulating sEng levels in these patients. Further studies are needed to confirm the counterhypertensive effect of this peptide in experimental models of preeclampsia and in clinical trials.
Finally, in addition to preeclampsia, increased levels of circulating sEng in serum, plasma, and other fluids in patients suffering from different diseases, including cancer and pathologies associated with endothelial dysfunction such as hypertension and diabetes mellitus, have been reported. 29, [45] [46] [47] Because elevated sEng levels are associated with poor prognosis in patients with metastatic solid tumors and with higher targetorgan damage in hypertensive and diabetic patients, 46 these studies may also help us understand the function of sEng in those pathological settings.
